3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
3
Phase 3
2
Phase 2
2
Phase 1/2
2
Phase 4
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
146
Breast Neoplasms
111
Prostatic Neoplasms
59
Neoplasms
54
Multiple Myeloma
54
Lung Neoplasms
49
Neoplasm Metastasis
40
Ovarian Neoplasms
33
Colorectal Neoplasms
32
Parkinson Disease 4, Autosomal Dominant Lewy Body
31
Leukemia, Lymphocytic, Chronic, B-Cell
31
Recurrence
26
Leukemia, Myeloid, Acute
26
Carcinoma, Renal Cell
25
Urinary Bladder Neoplasms
23
Triple Negative Breast Neoplasms
21
Small Cell Lung Carcinoma
21
Myasthenia Gravis
21
Endometrial Neoplasms
21
Carcinoma, Hepatocellular
21
Lymphoma, Large B-Cell, Diffuse
20
Squamous Cell Carcinoma of Head and Neck
19
Melanoma
18
Lymphoma, Follicular
18
Nasopharyngeal Carcinoma
17
Fallopian Tube Neoplasms
16
Pancreatic Neoplasms
15
Non-Muscle Invasive Bladder Neoplasms
15
Brain Neoplasms
15
Stomach Neoplasms
14
Interventions
Carboplatin
2
pembrolizumab
1
Pemetrexed
1
Paclitaxel
1
Nivolumab
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Carcinoma, Bronchogenic
×
90 days
×
Clear all
NCT06119581
2026-06-03
SUNRAY-01
Eli Lilly and Company
Phase 3
Recruiting
1,264 enrolled
NCT04564157
2026-05-05
NADIM-ADJUVANT
Fundación GECP
Phase 3
Active not recruiting
210 enrolled